Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment: Using Combinations of a Basal Insulin and a Glucagon-Like Peptide-1 Receptor Agonist.

This article presents the rationale and data for combining a basal insulin with a GLP-1RA, including as fixed-ratio products.